SV2010003751A - Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato - Google Patents

Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato

Info

Publication number
SV2010003751A
SV2010003751A SV2010003751A SV2010003751A SV2010003751A SV 2010003751 A SV2010003751 A SV 2010003751A SV 2010003751 A SV2010003751 A SV 2010003751A SV 2010003751 A SV2010003751 A SV 2010003751A SV 2010003751 A SV2010003751 A SV 2010003751A
Authority
SV
El Salvador
Prior art keywords
potentiators
isoxazol
derivatives
metabotropic glutamate
glutamate receptors
Prior art date
Application number
SV2010003751A
Other languages
English (en)
Inventor
Joseph Cacciola
James Empfield
James Folmer
Angela M Hunter
Scott Throner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SV2010003751A publication Critical patent/SV2010003751A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/08—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
    • A61B17/083—Clips, e.g. resilient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/08—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
    • A61B17/085—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound with adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/10—Surgical instruments, devices or methods, e.g. tourniquets for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/10—Surgical instruments, devices or methods, e.g. tourniquets for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
    • A61B17/105—Wound clamp magazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPUESTOS DE ACUERDO CON LA FORMULA I: (VER FORMULA); DONDE R1, R2, R3 Y R4 SON COMO LOS DEFINIDOS EN LA DESCRIPCIÓN, SALES FARMACÉUTICAMENTE ACEPTABLES, MÉTODOS DE FABRICACIÓN, LAS COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y MÉTODOS PARA USARLOS
SV2010003751A 2008-06-06 2010-12-06 Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato SV2010003751A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5948508P 2008-06-06 2008-06-06

Publications (1)

Publication Number Publication Date
SV2010003751A true SV2010003751A (es) 2011-04-14

Family

ID=41398335

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003751A SV2010003751A (es) 2008-06-06 2010-12-06 Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato

Country Status (40)

Country Link
US (4) US7790760B2 (es)
EP (2) EP2303872B1 (es)
JP (2) JP5476371B2 (es)
KR (1) KR20110020797A (es)
CN (1) CN102105466B (es)
AR (1) AR072016A1 (es)
AU (1) AU2009255784B2 (es)
BR (1) BRPI0913585A2 (es)
CA (1) CA2726925A1 (es)
CL (1) CL2010001348A1 (es)
CO (1) CO6321239A2 (es)
CR (1) CR11826A (es)
CU (1) CU23883B1 (es)
CY (1) CY1115301T1 (es)
DK (1) DK2303872T3 (es)
DO (1) DOP2010000375A (es)
EA (2) EA018412B1 (es)
EC (1) ECSP10010662A (es)
ES (1) ES2469837T3 (es)
GT (1) GT201000342A (es)
HK (2) HK1155744A1 (es)
HN (1) HN2010002582A (es)
HR (1) HRP20140451T1 (es)
IL (1) IL209622A0 (es)
MX (1) MX2010012949A (es)
MY (1) MY156552A (es)
NI (3) NI201000209A (es)
NZ (1) NZ590344A (es)
PE (1) PE20110028A1 (es)
PL (1) PL2303872T3 (es)
PT (1) PT2303872E (es)
RS (1) RS53392B (es)
SA (1) SA109300358B1 (es)
SI (1) SI2303872T1 (es)
SV (1) SV2010003751A (es)
TW (3) TWI382027B (es)
UA (1) UA107649C2 (es)
UY (1) UY31870A (es)
WO (1) WO2009148403A1 (es)
ZA (1) ZA201008611B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200927731A (en) 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
BRPI0920354A2 (pt) 2008-10-16 2017-06-27 Addex Pharmaceuticals Sa derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
RS53075B (en) 2009-05-12 2014-04-30 Janssen Pharmaceuticals Inc. 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
EP3129345B1 (en) 2014-04-06 2023-03-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
KR101663662B1 (ko) * 2015-06-17 2016-10-14 한국과학기술연구원 대사성 글루타메이트 수용체 1에 활성을 지닌 신규 아릴 아이소옥사졸 유도체
US20170145002A1 (en) * 2015-11-25 2017-05-25 Astrazeneca Ab Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
US10807680B2 (en) 2016-10-21 2020-10-20 National Tsing Hua University Mooring system and method for power generation systems and other payloads in water flows
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE620654C (de) 1933-04-29 1935-10-24 Smith & Sons Ltd S Geschwindigkeitsanzeiger
US3993617A (en) 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (en) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. 3-methyleneisoindolin-1-one derivative
TW219935B (es) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
KR19990082330A (ko) 1996-02-06 1999-11-25 미즈노 마사루 신규 화합물 및 이의 의약 용도
US6417362B1 (en) 1997-05-30 2002-07-09 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
WO1999026927A2 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
RU2257384C2 (ru) 2000-02-29 2005-07-27 Мицубиси Фарма Корпорейшн Новые производные циклического амида
MXPA03000923A (es) 2000-07-31 2003-06-09 Smithkline Beecham Plc Compuestos de carboxamida y su uso como antagonistas de un receptor 11cby humano.
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
AU2004226450A1 (en) 2003-03-26 2004-10-14 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
JP2007510629A (ja) 2003-10-22 2007-04-26 イーライ リリー アンド カンパニー 新規ｍｃｈ受容体アンタゴニスト
EP1713775A4 (en) 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
DE602005008558D1 (de) 2004-02-18 2008-09-11 Astrazeneca Ab Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
AU2005219791B2 (en) 2004-03-05 2011-06-09 Msd K.K. Diaryl-substituted five-membered heterocycle derivative
ES2526614T3 (es) 2004-03-05 2015-01-13 Nissan Chemical Industries, Ltd. Compuesto de benzamida sustituida con isoxazolina y agente de control de organismos nocivos
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
AU2005299797A1 (en) 2004-10-25 2006-05-04 Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors
US7960417B2 (en) 2005-02-24 2011-06-14 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
NZ564254A (en) 2005-05-18 2011-04-29 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
CN101309905A (zh) 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
ATE463495T1 (de) 2005-09-27 2010-04-15 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286

Also Published As

Publication number Publication date
NI201002091A (es) 2012-11-07
BRPI0913585A2 (pt) 2015-10-27
PE20110028A1 (es) 2011-02-11
TW201514173A (zh) 2015-04-16
PT2303872E (pt) 2014-06-23
SA109300358B1 (ar) 2012-11-03
HK1201255A1 (en) 2015-08-28
DOP2010000375A (es) 2010-12-31
US20100324044A1 (en) 2010-12-23
NI201002092A (es) 2012-11-07
KR20110020797A (ko) 2011-03-03
CU20100238A7 (es) 2011-11-15
CL2010001348A1 (es) 2011-03-25
JP2011522816A (ja) 2011-08-04
NI201000209A (es) 2012-11-07
JP2014114312A (ja) 2014-06-26
TWI477499B (zh) 2015-03-21
EA201001724A1 (ru) 2011-08-30
IL209622A0 (en) 2011-02-28
NZ590344A (en) 2012-07-27
EA018412B1 (ru) 2013-07-30
HRP20140451T1 (hr) 2014-08-01
EP2303872A4 (en) 2012-03-21
ECSP10010662A (es) 2011-01-31
MX2010012949A (es) 2010-12-15
HN2010002582A (es) 2012-08-27
AU2009255784B2 (en) 2012-08-16
TW201247658A (en) 2012-12-01
EA201300342A1 (ru) 2014-02-28
US20090306158A1 (en) 2009-12-10
CR11826A (es) 2011-02-04
DK2303872T3 (da) 2014-06-16
EP2303872B1 (en) 2014-04-16
TW201002699A (en) 2010-01-16
CN102105466B (zh) 2014-10-15
MY156552A (en) 2016-02-26
US7790760B2 (en) 2010-09-07
RS53392B (en) 2014-10-31
UA107649C2 (uk) 2015-02-10
UY31870A (es) 2010-01-29
US7888353B2 (en) 2011-02-15
ZA201008611B (en) 2012-05-30
CO6321239A2 (es) 2011-09-20
HK1155744A1 (en) 2012-05-25
CN102105466A (zh) 2011-06-22
JP5815765B2 (ja) 2015-11-17
PL2303872T3 (pl) 2014-08-29
SI2303872T1 (sl) 2014-06-30
EP2772492A1 (en) 2014-09-03
GT201000342A (es) 2015-02-16
CY1115301T1 (el) 2017-01-04
US8148372B2 (en) 2012-04-03
TWI382027B (zh) 2013-01-11
CU23883B1 (es) 2013-04-19
ES2469837T3 (es) 2014-06-20
CA2726925A1 (en) 2009-12-10
US20100317662A1 (en) 2010-12-16
AU2009255784A1 (en) 2009-12-10
WO2009148403A1 (en) 2009-12-10
EP2772492B1 (en) 2016-08-17
US20100022545A1 (en) 2010-01-28
AR072016A1 (es) 2010-07-28
JP5476371B2 (ja) 2014-04-23
US7781434B2 (en) 2010-08-24
EP2303872A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
SV2010003751A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
SV2010003472A (es) Compuestos de pirazol
CR10148A (es) Derivados de las benzamidas y heteroarenos
UY30858A1 (es) Nuevos derivados de fenil-(4-fenil-pirimidin-2-il)- aminas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
UY31639A1 (es) Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
UY30141A1 (es) Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP099370A (es) Derivados de hidantoína usados como inhibidores de mmp
UY32203A (es) Amino pirimidinas y su uso en terapia
UY30856A1 (es) Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk
UY29896A1 (es) Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
ECSP099565A (es) Compuesto de 2-amino pirimidina
UY31922A (es) Compuestos
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY30001A1 (es) Alquilsulfonamida quinolinas

Legal Events

Date Code Title Description
FD Lapse